Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Petr G Lokhov & Elena E Balashova. (2015) Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC). Human Vaccines & Immunotherapeutics 11:3, pages 689-698.
Read now
Read now
Jae-il Roh, Young Hoon Sung & Han-Woong Lee. (2013) Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer. OncoTargets and Therapy 6, pages 1161-1166.
Read now
Read now
Fernando Aranda, Erika Vacchelli, Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2013) Trial Watch. OncoImmunology 2:12.
Read now
Read now
Else-Marit Inderberg-Suso, Sissel Trachsel, Kari Lislerud, Anne-Marie Rasmussen & Gustav Gaudernack. (2012) Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. OncoImmunology 1:5, pages 670-686.
Read now
Read now
VE Shaw, DJ Naisbitt, E Costello, W Greenhalf, BK Park, JP Neoptolemos & GW Middleton. (2010) Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Review of Vaccines 9:9, pages 1007-1016.
Read now
Read now
Olivia Simmons, Mitchell Magee & John Nemunaitis. (2010) Current vaccine updates for lung cancer. Expert Review of Vaccines 9:3, pages 323-335.
Read now
Read now
Articles from other publishers (56)
Jung Hyun Jo, Yong-Tae Kim, Ho Soon Choi, Ho Gak Kim, Hong Sik Lee, Young Woo Choi, Dong Uk Kim, Kwang Hyuck Lee, Eui Joo Kim, Joung-Ho Han, Seung Ok Lee, Chang-Hwan Park, Eun Kwang Choi, Jae Woo Kim, Jae Yong Cho, Woo Jin Lee, Hyungsik Roger Moon, Mi-Suk Park, Sangjae Kim & Si Young Song. (2023) Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial. British Journal of Cancer.
Crossref
Crossref
Keerti Vishwakarma, Rajdeep Dey & Hardik Bhatt. (2023) Telomerase: A prominent oncological target for development of chemotherapeutic agents. European Journal of Medicinal Chemistry 249, pages 115121.
Crossref
Crossref
Davor Juretić. (2022) Designed Multifunctional Peptides for Intracellular Targets. Antibiotics 11:9, pages 1196.
Crossref
Crossref
Ji Won Kim, Miso Park, Suntae Kim, Sung Chul Lim, Hyung Shik Kim & Keon Wook Kang. (2021) Anti-metastatic effect of GV1001 on prostate cancer cells; roles of GnRHR-mediated Gαs-cAMP pathway and AR-YAP1 axis. Cell & Bioscience 11:1.
Crossref
Crossref
Seong-Ho Koh, Hyuk Sung Kwon, Seong Hye Choi, Jee Hyang Jeong, Hae Ri Na, Chan Nyoung Lee, YoungSoon Yang, Ae Young Lee, Jae-Hong Lee, Kyung Won Park, Hyun Jeong Han, Byeong C. Kim, Jin Se Park, Jee-Young Lee, Sangjae Kim & Kyu-Yong Lee. (2021) Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimer's Research & Therapy 13:1.
Crossref
Crossref
Hyuk Sung Kwon, Ye Eun Kim, Hyun-Hee Park, Jeong-Woo Son, Hojin Choi, Young Joo Lee, Hyun Young Kim, Kyu-Yong Lee & Seong-Ho Koh. (2021) Neuroprotective Effects of GV1001 in Animal Stroke Model and Neural Cells Subject to Oxygen-Glucose Deprivation/Reperfusion Injury. Journal of Stroke 23:3, pages 420-436.
Crossref
Crossref
Huakan Zhao, Lei Wu, Guifang Yan, Yu Chen, Mingyue Zhou, Yongzhong Wu & Yongsheng Li. (2021) Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Ali Salimi-Jeda, Fariba Badrzadeh, Maryam Esghaei & Asghar Abdoli. (2021) The role of telomerase and viruses interaction in cancer development, and telomerase-dependent therapeutic approaches. Cancer Treatment and Research Communications 27, pages 100323.
Crossref
Crossref
Lele Wu, Kerem Fidan, Jae-Young Um & Kwang Seok Ahn. (2020) Telomerase: Key regulator of inflammation and cancer. Pharmacological Research 155, pages 104726.
Crossref
Crossref
Nicola Relitti, Akella P. Saraswati, Stefano Federico, Tuhina Khan, Margherita Brindisi, Daniela Zisterer, Simone Brogi, Sandra Gemma, Stefania Butini & Giuseppe Campiani. (2020) Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. Current Topics in Medicinal Chemistry 20:6, pages 433-457.
Crossref
Crossref
Rajendra Prasad, Deeksha Pal & Wajid Mohammad. (2020) Therapeutic Targets in Telomerase and Telomere Biology of Cancers. Indian Journal of Clinical Biochemistry 35:2, pages 135-146.
Crossref
Crossref
Jenny Roggisch, Thorsten Ecke & Stefan Koch. (2020) Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer. Urologic Oncology: Seminars and Original Investigations 38:3, pages 77.e17-77.e25.
Crossref
Crossref
Eun Kyoung Lee, Young Joo Kim, Won-Jun Shon & Hyeong Gon Yu. (2020) A telomerase-derived peptide vaccine inhibits laser-induced choroidal neovascularization in a rat model. Translational Research 216, pages 30-42.
Crossref
Crossref
Sang-Yeon Lee, Jae Joon Han, Sang-Youp Lee, Gaon Jung, Hyun Jin Min, Jae-Jin Song & Ja-Won Koo. (2020) Outcomes of Peptide Vaccine GV1001 Treatment in a Murine Model of Acute Noise-Induced Hearing Loss. Antioxidants 9:2, pages 112.
Crossref
Crossref
Ji Won Kim, Dharmendra K Yadav, Soo Jin Kim, Moo-Yeol Lee, Jung-Min Park, Bum Seok Kim, Mi-hyun Kim, Hyeung-geun Park & Keon Wook Kang. (2019) Anti-cancer effect of GV1001 for prostate cancer: function as a ligand of GnRHR. Endocrine-Related Cancer, pages 147-162.
Crossref
Crossref
Brankica Filipić & Zorica Stojić-Vukanić. (2019) Active immunotherapy of cancer: An overview of therapeutic vaccines. Arhiv za farmaciju 69:6, pages 490-506.
Crossref
Crossref
Ganiou Assani, Yudi Xiong, Fuxiang Zhou & Yunfeng Zhou. (2018) Effect of therapies-mediated modulation of telomere and/or telomerase on cancer cells radiosensitivity. Oncotarget 9:79, pages 35008-35025.
Crossref
Crossref
So Young Kim, Gaon Jung, Ye Ji Shim & Ja-Won Koo. (2018) The Novel Peptide Vaccine GV1001 Protects Hearing in a Kanamycin-induced Ototoxicity Mouse Model. Otology & Neurotology 39:8, pages e731-e737.
Crossref
Crossref
Kyeong Kim, Hun Yang, Seung‑Cheol Chang, Young‑Mi Kim, Kwang Lee, Byung Lee & Hyung Kim. (2018) Potential repositioning of GV1001 as a therapeutic agent for testosterone‑induced benign prostatic hyperplasia. International Journal of Molecular Medicine.
Crossref
Crossref
Ga Eun Kim, Ae Ryang Jung, Mee Young Kim, Joseph Bada Lee, Ji Houn Im, Kyu Won Lee, Yong Hyun Park & Ji Youl Lee. (2018) GV1001 Induces Apoptosis by Reducing Angiogenesis in Renal Cell Carcinoma Cells Both In Vitro and In Vivo. Urology 113, pages 129-137.
Crossref
Crossref
Michel M Ouellette. 2005. Encyclopedia of Life Sciences. Encyclopedia of Life Sciences
1
10
.
Wolfgang Lilleby, Gustav Gaudernack, Paal F. Brunsvig, Ljiljana Vlatkovic, Melanie Schulz, Kate Mills, Knut H?kon Hole & Else Marit Inderberg. (2017) Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Cancer Immunology, Immunotherapy 66:7, pages 891-901.
Crossref
Crossref
In Ah Choi, Ji Yong Choi, Sundo Jung, Fathihah Basri, Seho Park & Eun Young Lee. (2017) GV1001 immunotherapy ameliorates joint inflammation in a murine model of rheumatoid arthritis by modifying collagen-specific T-cell responses and downregulating antigen-presenting cells. International Immunopharmacology 46, pages 186-193.
Crossref
Crossref
Fangjun Chen & Fanyan Meng. 2017. Personalized Management of Gastric Cancer. Personalized Management of Gastric Cancer
131
147
.
Mohammad A. Jafri, Shakeel A. Ansari, Mohammed H. Alqahtani & Jerry W. Shay. (2016) Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Medicine 8:1.
Crossref
Crossref
Saifullah Afridi, Daniel C. Hoessli & Muhammad Waqar Hameed. (2016) Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications. Immunological Reviews 272:1, pages 151-168.
Crossref
Crossref
Hong Kim, Myung-Soo Choi, Kyung-Soo Inn & Bum-Joon Kim. (2016) Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner. Scientific Reports 6:1.
Crossref
Crossref
Yinnan Chen & Yanmin Zhang. (2016) Functional and mechanistic analysis of telomerase: An antitumor drug target. Pharmacology & Therapeutics 163, pages 24-47.
Crossref
Crossref
Hyun-Hee Park, Hyun-Jung Yu, Sangjae Kim, Gabseok Kim, Na-Young Choi, Eun-Hye Lee, Young Joo Lee, Moon-Young Yoon, Kyu-Yong Lee & Seong-Ho Koh. (2016) Neural stem cells injured by oxidative stress can be rejuvenated by GV1001, a novel peptide, through scavenging free radicals and enhancing survival signals. NeuroToxicology 55, pages 131-141.
Crossref
Crossref
Malgorzata E. Wojtowicz, Barbara K. Dunn & Asad Umar. (2016) Immunologic approaches to cancer prevention—current status, challenges, and future perspectives. Seminars in Oncology 43:1, pages 161-172.
Crossref
Crossref
Seoung-Ae Lee, Jinhee Kim, Jihyun Sim, Sang-Gyune Kim, Yoon-Hoh Kook, Chung-Gyu Park, Hang-Rae Kim & Bum-Joon Kim. (2016) A telomerase-derived peptide regulates reactive oxygen species and hepatitis C virus RNA replication in HCV-infected cells via heat shock protein 90. Biochemical and Biophysical Research Communications 471:1, pages 156-162.
Crossref
Crossref
Lysanne Lievense, Joachim Aerts & Joost Hegmans. 2016. Lung Cancer and Personalized Medicine. Lung Cancer and Personalized Medicine
59
90
.
Gaute Lund Hansen, Gustav Gaudernack, Paal Fredrik Brunsvig, Milada Cvancarova & Jon Amund Kyte. (2015) Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. Cancer Immunology, Immunotherapy 64:12, pages 1609-1621.
Crossref
Crossref
Jeanne Galaine, Christophe Borg, Yann Godet & Olivier Adotévi. (2015) Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines 3:3, pages 490-502.
Crossref
Crossref
Maurizio Zanetti. (2015) Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics. The Journal of Immunology 194:5, pages 2049-2056.
Crossref
Crossref
Hyun Yang & Dong Seok Kim. 2015. Peptide and Protein Vaccines. Peptide and Protein Vaccines
1
14
.
YONG QIN, HONG GUO, BO TANG & SHI-MING YANG. (2014) The non-reverse transcriptase activity of the human telomerase reverse transcriptase promotes tumor progression (Review). International Journal of Oncology 45:2, pages 525-531.
Crossref
Crossref
Hyun-Hee Park, Kyu-Yong Lee, Sangjae Kim, Jessica Woojin Lee, Na-Young Choi, Eun-Hye Lee, Young Joo Lee, Sang-Hun Lee & Seong-Ho Koh. (2014) The novel vaccine peptide GV1001 effectively blocks β-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase. Neurobiology of Aging 35:6, pages 1255-1274.
Crossref
Crossref
T.Y. Koo, J.-J. Yan & J. Yang. (2014) Protective Effect of Peptide GV1001 Against Renal Ischemia-Reperfusion Injury in Mice. Transplantation Proceedings 46:4, pages 1117-1122.
Crossref
Crossref
Bu-Kyung Kim, Bo-Ram Kim, Hyun-Joo Lee, Seoung-Ae Lee, Byoung-Jun Kim, Hong Kim, Yu-Sub Won, Won-Jun Shon, Na-Rae Lee, Kyung-Soo Inn & Bum-Joon Kim. (2014) Tumor-suppressive effect of a telomerase-derived peptide by inhibiting hypoxia-induced HIF-1α-VEGF signaling axis. Biomaterials 35:9, pages 2924-2933.
Crossref
Crossref
Lucia Picariello. (2014) Telomerase activity: An attractive target for cancer therapeutics. World Journal of Pharmacology 3:4, pages 86.
Crossref
Crossref
Sonia Quaratino, Ulf Forssmann & Jens-Peter Marschner. 2017. Cancer Vaccines. Cancer Vaccines
1
31
.
Seoung-Ae Lee, Bo-Ram Kim, Bu-Kyung Kim, Dong-Won Kim, Won-Jun Shon, Na-Rae Lee, Kyung-Soo Inn & Bum-Joon Kim. (2013) Heat shock protein-mediated cell penetration and cytosolic delivery of macromolecules by a telomerase-derived peptide vaccine. Biomaterials 34:30, pages 7495-7505.
Crossref
Crossref
Maria Ruden & Neelu Puri. (2013) Novel anticancer therapeutics targeting telomerase. Cancer Treatment Reviews 39:5, pages 444-456.
Crossref
Crossref
Kristen M. Smith & Catriona H. M. Jamieson. 2006. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Encyclopedia of Molecular Cell Biology and Molecular Medicine.
Paal Fr. Brunsvig, Jon Amund Kyte, Christian Kersten, Stein Sundstrøm, Mona Møller, Marta Nyakas, Gaute L. Hansen, Gustav Gaudernack & Steinar Aamdal. (2011) Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial. Clinical Cancer Research 17:21, pages 6847-6857.
Crossref
Crossref
Luigi Aurisicchio & Gennaro Ciliberto. (2011) Emerging Cancer Vaccines: The Promise of Genetic Vectors. Cancers 3:3, pages 3687-3713.
Crossref
Crossref
Shanna Rajpar, Lionel Guittat & Jean-Louis Mergny. (2011) Télomères : un Nobel pour le début de la fin. Bulletin du Cancer 98:9, pages 999-1009.
Crossref
Crossref
Jon Amund Kyte, Gustav Gaudernack, Svein Dueland, Sissel Trachsel, Lars Julsrud & Steinar Aamdal. (2011) Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients. Clinical Cancer Research 17:13, pages 4568-4580.
Crossref
Crossref
Michel M. Ouellette, Woodring E. Wright & Jerry W. Shay. (2011) Targeting telomerase-expressing cancer cells. Journal of Cellular and Molecular Medicine 15:7, pages 1433-1442.
Crossref
Crossref
Christoph Schlapbach, Daniel Yerly, Barbara Daubner, Nikhil Yawalkar & Robert E. Hunger. (2011) Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma. Journal of Dermatological Science 62:2, pages 75-83.
Crossref
Crossref
Simone Polvani, Massimo Calamante, Valeria Foresta, Elisabetta Ceni, Alessandro Mordini, Alessandro Quattrone, Massimo D'Amico, Claudio Luchinat, Ivano Bertini & Andrea Galli. (2011) Acycloguanosyl 5′-thymidyltriphosphate, a Thymidine Analogue Prodrug Activated by Telomerase, Reduces Pancreatic Tumor Growth in Mice. Gastroenterology 140:2, pages 709-720.e9.
Crossref
Crossref
F. Pandolfi, R. Cianci, D. Pagliari, F. Casciano, C. Bagalà, A. Astone, R. Landolfi & C. Barone. (2011) The Immune Response to Tumors as a Tool toward Immunotherapy. Clinical and Developmental Immunology 2011, pages 1-12.
Crossref
Crossref
Michele Chen & Sandra W. McLeskey. (2010) Telomere-Based Cancer Treatment. Clinical Journal of Oncology Nursing 14:6, pages 720-726.
Crossref
Crossref
A. Heller, I. Zörnig, T. Müller, K. Giorgadze, C. Frei, T. Giese, F. Bergmann, J. Schmidt, J. Werner, M. W. Buchler, D. Jaeger & N. A. Giese. (2010) Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer. Cancer Immunology, Immunotherapy 59:9, pages 1389-1400.
Crossref
Crossref
Olivier AdotéviKarine MollierChristine Neuveut, Magalie DossetPatrice Ravel, Wolf-Hervé FridmanEric TartourPierre CharneauSimon Wain-HobsonPierre Langlade-Demoyen. (2010) Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood 115:15, pages 3025-3032.
Crossref
Crossref